DURECT Corporation (DRRX) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $4. Rodman & Renshaw advised their investors in a research report released on Apr 25, 2016.
DURECT Corporation opened for trading at $1.35 and hit $1.4 on the upside on Friday, eventually ending the session at $1.38, with a gain of 3.76% or 0.05 points. The heightened volatility saw the trading volume jump to 2,98,999 shares. Company has a market cap of $168 M.
In a different news, on Mar 16, 2016, Felix Theeuwes (Chairman and CSO) purchased 70,000 shares at $1.41 per share price. According to the SEC, on Mar 16, 2016, Terrence F Blaschke (director) purchased 3,000 shares at $1.35 per share price. On Mar 16, 2016, Armand Neukermans (director) purchased 18,000 shares at $1.39 per share price, according to the Form-4 filing with the securities and exchange commission.
Durect Corporation is a specialty pharmaceutical company. The Company is focused on the development of pharmaceuticals based on its drug delivery technology platforms chemical entities derived from its Epigenomic Regulator Program and its engagement in drug development. Its research and development programs fall into one of two categories: Drug Delivery Programs in which it applies its formulation and technologies to pharmaceutical ingredients and New Chemical Entities derived from its Epigenomic Regulator Program in which it discovers and develops molecules. It also manufactures and sells osmotic pumps and biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. Its product pipeline consists of seven investigational drug candidates in clinical development: REMOXY (ORADUR-Oxycodone) POSIDUR (SABER-Bupivacaine) ELADUR (TRANSDUR-Bupivacaine) Relday ORADUR-ADHD ORADUR-Opioid and SABER-based ophthalmic.